I diopathic pulmonary fibrosis (IPF) 3 likely results from an abnormal healing response to injury of the alveolar surface in the lung (1) . Development of the disease is characterized by alveolar epithelial cell injury, inflammatory cell accumulation, fibroblast hyperplasia, and collagen deposition. Ultimately, IPF results in loss of lung elasticity and reduction of the alveolar surface area, causing impairment of gas exchange and severe compromises in pulmonary function (2) .
The pathogenesis of pulmonary fibrosis is not completely understood, but is thought to involve expansion of local lung fibroblasts as well as recruitment of fibrocytes to the lung (3) (4) (5) (6) (7) (8) . Fibrocytes are bone marrow-derived cells which share phenotypic and functional properties of both leukocytes and mesenchymal cells. They are characterized by the expression of CD45 or CD34 and collagen 1. They directly contribute to extracellular matrix generation and promote fibrotic responses through the synthesis of fibroblast products collagen 1, collagen 3, and fibronectin (3) (4) (5) (6) (7) (8) (9) . Fibrocytes migrate to sites of injury in a diverse group of lung diseases where they play a crucial role in tissue remodeling and repair (6 -8) . At sites of tissue injury, fibrocytes synthesize extracellular matrix and express fibrogenic cytokines such as IL-1␤, TNF-␣, CCL2, CXCL1, platelet-derived growth factor ␣, TGF-␤1, and M-CSF (4) . Fibrocyte recruitment is a complex biological phenomenon mediated by a variety of ligands and receptors. Fibrocytes have been shown to be recruited to the lungs by CXCR4, CCR7, and CCR2-mediated signals (6, 7) . Interestingly, fibrocytes are recruited to both bleomycin-and FITC-treated lungs, and the severity of the disease correlates with the number of fibrocytes recruited (6, 7) .
Eicosanoids are lipid mediators derived from arachidonic acid metabolism and they can promote or inhibit fibrotic lung disease by influencing mesenchymal cell activity. Leukotrienes (LTs) promote fibroblast chemotaxis, fibroblast proliferation, and collagen synthesis (10 -12) . PGs PGE 2 and prostacyclin inhibit such profibrotic responses (13) (14) (15) . Derangements of eicosanoid synthesis are present in fibrotic lungs. IPF patients exhibit underproduction of PGE 2 (16) and overproduction of LTs (12) . Levels of both classes of LTs-cysteinyl LTs (CysLTs; LTC 4 , LTD 4 , and LTE 4 ) and LTB 4 are elevated in these patients. Alveolar macrophages (AMs) are a primary source of LT synthesis and contribute to increased production of LTs in IPF lung homogenates (12) .
Animal models of fibrotic lung disease are also characterized by increased LT production following lung injury (17) . Previously, we have demonstrated that mice that are genetically deficient in 5-lipoxygenase (5-LO), an enzyme necessary for LT generation, are protected from bleomycin-induced pulmonary fibrosis (17) . In addition, treatment with the CysLT receptor 1 (CysLT1) antagonists, MK571 (18) or montelukast (19) , also limit bleomycin-induced fibrotic changes. Strong evidence therefore indicates that LTs and fibrocytes both participate in pulmonary fibrosis. LTs exert direct effects on migration (20) , proliferation (21) , and matrix protein synthesis (22) by fibroblasts, but the effects of LTs on fibrocytes remain unknown. In this study, we present novel evidence for LT regulation of fibrocytes during fibrogenesis.
Materials and Methods

Mice
C57BL/6 and 5-LO Ϫ/Ϫ mice backcrossed to this background were purchased from The Jackson Laboratory. Due to limited availability of these mice, however, some experiments were performed with 5-LO Ϫ/Ϫ (129-Alox5 tm1Fun/J ) (23) and strain-matched (129SvEv) wild-type (WT) mice bred in the University of Michigan Unit for Laboratory Animal Medicine from breeders originally obtained from The Jackson Laboratory. Both female and male mice were used. Mice were studied between 2 and 5 mo of age. Animal protocols were approved by the University Committee on the Use and Care of Animals.
FITC model of pulmonary fibrosis
FITC inoculation was performed as previously described (24) . Briefly, mice were anesthetized with ketamine and xylazine. The trachea was exposed and entered with a needle under direct visualization. FITC (28 mg; Sigma-Aldrich) was dissolved in 10 ml of sterile PBS, vortexed extensively, and sonicated for 30 s. This slurry was transferred to multiuse vials and vortexed extensively before each 50-l aliquot was removed for intratracheal injection using a 23-gauge needle. Collagen accumulation in the lung was measured by hydroxyproline assay on day 21 after FITC treatment as we have previously described (6) .
Reagents used
CysLT1 antagonists MK571 and Ly171883 were purchased from BIOMOL. LTD 4 was purchased from Cayman Chemical. Abs against human CysLT1 (rabbit polyclonal, sc-25448) and murine CysLT2 (goat polyclonal, sc-27097) were purchased from Santa Cruz Biotechnology. Appropriate secondary Abs conjugated to peroxidase for Western blotting were purchased from Pierce.
Fibrocyte isolation
Murine lungs were perfused with 5 ml of normal saline and removed using aseptic conditions. Lungs were minced with scissors in DMEM complete medium containing 10% FCS. Lungs from a single animal were placed in 15 ml of medium in tissue culture flasks. Mesenchymal cells were allowed to grow out of the minced tissue and when cells reached 70% confluence they were passaged using trypsin digestion. Mesenchymal cells were grown for 14 days before being harvested by trypsin digestion. Cells were stained with anti-CD45 Abs coupled to magnetic beads (Miltenyi Biotec). Labeled cells were then sorted by binding the cell population to MS-or LS-positive selection columns using a SuperMACS apparatus (Miltenyi Biotec) according to manufacturer's instructions. Cells were then washed extensively. CD45 ϩ cells were retained on the column and can be removed by flushing the column with buffer once it is removed from the magnetic field. CD45
Ϫ cells were collected in the original flow-through. For extra purity, CD45 ϩ cells were sometimes reapplied to a second MS-positive selection column. The absolute number of lung fibrocytes was determined by counting the cells that were retained on the column by a hemocytometer. Immunohistochemical staining or flow cytometry staining on this population confirmed that these cells were CD45 ϩ CD13 ϩ col 1 ϩ . For isolation of human fibrocytes, 20 ml of peripheral blood was collected in heparinized Vacutainers (BD Biosciences) from consenting normal volunteers. Whole blood was diluted 1/1 with 0.9% normal saline. Thirty milliliters of the diluted whole blood was layered onto 15 ml of Ficoll-Hypaque in a 50-ml conical tube and centrifuged at 1200 rpm for 45 min. The buffy coat layer was removed, washed three times in serum-free medium (SFM), and the cell pellet was then cultured in complete medium containing 20% FCS for 14 days. At this time point, adherent cells were Ͼ95% fibrocytes as determined by flow cytometry for CD45 and procollagen 1 expression. Fibrocytes were trypsinized and replated in SFM for proliferation assays or Western blot analysis. These experiments were approved by the University of Michigan Institutional Review Board. VO 4 , and 1/100 dilution of Calbiochem Protease Cocktail Set II (Calbiochem-Novabiochem)) was added to each sample. Lysates were assayed for total protein concentration using the DC Protein Assay (Bio-Rad). Four micrograms of protein from each sample was then analyzed for expression of CysLT1, CysLT2, or ␤-actin using methods that have been described previously (25) .
Proliferation assay
Chemotaxis assay
Lung mince cultures were grown for 14 days and serum-starved for 24 h before magnetic purification of CD45 ϩ fibrocytes. Purified fibrocytes (1 ϫ 10 6 /ml) were plated in the top wells of Boyden chambers and migration (cells per high-powered field) was measured in response to 0.1% FBS (negative control), fibronectin (positive control, 100 g/ml; Sigma-Aldrich) or LTD 4 (10 nM; Cayman Chemical) through gelatin-coated 5-to 8-m filters. Checkerboard analysis proved that the migration was directional.
Semiquantitative real-time PCR
Semiquantitative real-time RT-PCR was performed on an Applied Biosystems Prism 7000 thermocycler. Gene-specific primers and probes were designed using Primer Express software (PerkinElmer/PE Applied Biosystems). The sequences for all primers and probes are found in Table I . Briefly, the reaction mixture contained 250 ng of RNA, 12.5 l of TaqMan 2ϫ Universal PCR Master Mix, 0.625 l of 40ϫ MultiScribe and RNase Inhibitor Mix (Applied Biosystems and Roche), 250 nM FAM probe, and forward and reverse primers at 300 nM in a final volume of 25 l. For each experiment, samples were run in triplicate. The average cycle threshold (C T ) was determined for each sample, and relative gene expression was calculated using the comparative C T method (26) , which assesses the difference in gene expression between the gene of interest and an internal standard gene (␤-actin) for each sample to generate the ⌬⌬C T . The average of the control sample (AMs) was set to 1 for each experiment and the relative gene expression for each experimental sample was compared with that.
Expression of the LTB 4 receptors, BLT1 and BLT2, were examined by 40 cycles of conventional RT-PCR using primers and probes listed in Table  I . Southern blotting using internal probes confirmed the absence of a BLT1 or BLT2 signal in isolated fibrocytes. Neutrophils were used as a positive control for BLT1 and BLT2 amplification. 
Collagenase digestions of whole lung
For some experiments, lungs were digested with collagenase on day 5 after FITC treatment according to a previously published protocol (27) . Lungs were excised, minced, and enzymatically digested for 30 min using 15 ml/lung of digestion buffer (RPMI 1640, 5% FCS, antibiotics, and 1 mg/ml collagenase; Boehringer Mannheim) and 30 g/ml DNase (Sigma-Aldrich). The cell suspension and undigested fragments were further dispersed by repeated passage through the bore of a 10-ml syringe without a needle. The total cell suspension was pelleted and any contaminating erythrocytes were eliminated by lysis in ice-cold NH 4 Cl buffer (0.829% NH 4 Cl, 0.1% KHCO 3 , and 0.0372% Na 2 EDTA, pH 7.4). The pellet was resuspended in 5 ml of complete medium (RPMI 1640, 5% FCS, and 1% penicillin/streptomycin) and dispersed by 20 passages through a 5-ml syringe. The dispersed cells were filtered through a Nytex filter (Tetko) to remove clumps. The total volume was brought up to 10 ml with complete medium. An equal volume of 40% Percoll (Sigma-Aldrich) was added, and the cells were centrifuged at 3000 rpm for 30 min (room temperature) with no brake. The cell pellets were resuspended in complete medium and leukocytes were counted on a hemocytometer in the presence of trypan blue. Cells were Ͼ90% viable by trypan blue exclusion. Recovered leukocytes were analyzed by flow cytometry.
Bronchoalveolar lavage (BAL)
Alveolar cells were obtained via ex vivo lung lavage using a previously described protocol (28) . Briefly, these cells were collected in lavage fluid consisting of complete medium (DMEM, 1% penicillin-streptomycin, 1% L-glutamine, 10% FCS, and 0.1% Fungizone) and 5 mM EDTA. The cells were enumerated by counting on a hemocytometer before use. In some experiments, alveolar cells were enriched by a 1-h adherence step in SFM before being cultured for 24 h in complete medium. The adherent fraction consists largely of AMs in untreated mice and of AMs, fibrocytes, and neutrophils after FITC treatment. In some cultures, 5 M Ca 2ϩ ionophore (A23187) was added for 1 h in SFM as a maximal stimulus for LT synthesis. In other experiments, BAL cell pellets were cultured for 14 days ex vivo.
Flow cytometry analysis
Cells obtained by collagenase digestion or BAL were incubated for 15 min on ice with Fc block (clone 24G2; BD Pharmingen) before surface staining with CD45-PerCP-Cy5.5 (BD Pharmingen) followed by fixation and permeabilization using the BD Pharmingen Cytofix/Cytoperm kit according to the manufacturer's instructions. Cells were then blocked with goat IgG before staining for collagen 1 (rabbit anti-mouse; Accurate Chemical & Scientific) followed by a donkey anti-rabbit PE secondary Ab (Jackson ImmunoResearch Laboratories). Cells were analyzed on a flow cytometer (FACScan; BD Biosciences). Human fibrocytes were stained with antihuman CD45 FITC (BD Biosciences) and, following a blocking step, collagen was assessed using anti-human procollagen I Ab from Santa Cruz Biotechnology followed by a donkey anti-goat PE secondary Ab from Jackson ImmunoResearch Laboratories.
Assay of LTs
The measurements for CysLTs and LTB 4 were performed on lung homogenates and alveolar cell and fibrocyte supernatants using enzyme immunoassay (EIA) kits obtained from Cayman Chemical according to the manufacturer's instructions. The lower limit of detection was 10 pg/ml. Lipids were first extracted from lung homogenates using C 18 SepPak cartridges according to our previously published protocol (17) .
Statistical analysis
When analyzing three or more groups, statistical significance was measured by ANOVA. For comparison between data from two groups, data were analyzed by Student's t test. A p Ͻ 0.05 was considered significant.
Results
FITC treatment stimulates CysLT production
To verify that FITC deposition resulted in CysLT release, we treated WT (C57BL/6) mice with FITC on day 0 and homogenized lungs on days 0, 3, and 7. Lipids were extracted from lung homogenates using C 18 SepPak cartridges. Levels of CysLTs increased on days 3 and 7 after FITC treatment (Fig. 1A) . We next measured the production of CysLTs from alveolar cells purified by BAL on days 0 and 7 after FITC treatment. Plastic-adherent cells from the BAL, which likely include AMs, fibrocytes, and neutrophils, were cultured for 1 h in the presence or absence of the calcium ionophore A23187 (Fig. 1B) to provide a maximal stimulus for arachidonic acid release and LT synthesis. Synthesis of CysLTs was significantly elevated in cells purified from FITCtreated mice ( p ϭ 0.0002). Similar results were seen in FITCtreated 129SvEv mice. These results indicate that inflammatory cells likely contribute to increased lung CysLTs after FITC treatment.
5-LO Ϫ/Ϫ mice are protected from FITC-induced fibrosis
Previous studies have demonstrated that 5-LO Ϫ/Ϫ mice are protected from bleomycin-induced lung fibrosis (17) . To verify that 5-LO Ϫ/Ϫ mice were protected from FITC-induced fibrosis, we injected WT (129SvEv) or 5-LO Ϫ/Ϫ mice with FITC on day 0 and measured collagen accumulation in the lungs by hydroxyproline assay on day 21 after FITC treatment. Fig. 1C demonstrates that 5-LO Ϫ/Ϫ mice are significantly protected from FITC-induced fibrosis.
Fibrocytes express both the CysLT1 and CysLT2 receptors
We next investigated the expression of LT receptors on fibrocytes. Fibrocytes were purified from C57BL/6 mice and total mRNA was FIGURE 1. FITC deposition results in release of CysLTs. A, WT (C57BL/6) mice were injected with FITC on day 0. Lung homogenates were collected on days 0, 3, and 7 after FITC treatment. Lipids were extracted and levels of CysLTs were determined by specific EIA, n ϭ 4 -6/ group, p Ͻ 0.05 by ANOVA at day 7. B, Mice were injected with FITC on day 0 and plastic-adherent BAL cells were harvested on day 0 or 7. These cells (which consist mostly of AMs but may contain some fibrocytes and neutrophils after FITC treatment) were cultured at 5 ϫ 10 5 /ml for 1 h in the presence of 5 M A23187 and supernatants were analyzed for CysLTs via specific EIA, n ϭ 4, p ϭ 0.0002 by Student's t test. C, WT (129SvEv) or 5-LO Ϫ/Ϫ mice were injected with FITC intratracheally on day 0. On day 21, mice were euthanized, lungs were removed, and collagen content was determined via hydroxyproline assay, n ϭ 10, p ϭ 0.01 by Student's t test.
prepared. The mRNA was analyzed for expression of the two CysLT receptors, cysLT1 and cysLT2, by real-time RT-PCR using mRNA levels in AMs as a positive control. To directly compare the expression of CysLT1 and CysLT2 in fibrocytes, the expression of CysLT1 in AMs was set to 1 and then the expression of CysLT1 and CysLT2 on fibrocytes was compared with this value. As noted in Fig. 2A , the levels of CysLT1 mRNA were ϳ12-fold higher in fibrocytes compared with AMs. The levels of CysLT2 mRNA on fibrocytes were approximately one-half the level of CysLT1 mRNA. We next analyzed the expression of CysLT1 and CysLT2 protein in isolated murine AMs, fibrocytes, and fibroblasts by Western blot analysis (Fig. 2B) . Despite the differences in mRNA levels noted above, the levels of CysLT1 protein appear similar in both fibrocytes and AMs. In contrast, CysLT1 is expressed at low levels in fibroblasts. CysLT2 protein levels in AMs and fibrocytes appear similar. Interestingly, the level of CysLT2 noted in fibroblasts is greater than the levels on either fibrocytes or AMs. CysLT1 and CysLT2 protein levels in fibrocytes isolated from human peripheral blood were detected at similar ratios to those found in cells from mice (Fig. 2C) . The receptors for LTB 4 , BLT1, and BLT2, were analyzed by conventional RT-PCR followed by Southern blotting using internal probes, but were found to be undetectable in murine fibrocytes (data not shown). Thus, LT 3. Fibrocytes produce LTs. Fibrocytes and fibroblasts were purified from WT (C57BL/6) mice and cultured at 10 5 /ml overnight in SFM. The next morning, A23187, a calcium ionophore was added for 1 h at 5 M. Supernatants were collected and analyzed for the production of CysLTs by specific EIA, n ϭ 4. Ionophore-stimulated fibrocytes produced significantly more CysLTs than did fibroblasts, p ϭ 0.002 by Student's t test.
FIGURE 4. LTs regulate fibrocyte proliferation.
A, Fibrocytes were purified from lung mince cultures at day 14 from either WT (C57BL/6) or 5-LO Ϫ/Ϫ mice. Fibrocytes were cultured at 2 ϫ 10 5 /ml in complete medium for 48 h and proliferation was measured via [ 3 H]thymidine incorporation over the final 16 h, n ϭ 6, p ϭ 0.0025 by Student's t test. B, Fibrocytes were purified from WT (129SvEv) mice or strain-matched 5-LO Ϫ/Ϫ mice (C) and cultured at 2 ϫ 10 5 /ml in SFM with or without 1-100 nM LTD 4 or LTC 4 for 24 h. Proliferation was measured over the final 16 h as previously described, n ϭ 6; ‫,ء‬ p Ͻ 0.05 by ANOVA. effects on fibrocytes are likely mediated via the CysLT1 and/or CysLT2 receptors.
Fibrocytes produce CysLTs
Although it is known that leukocytes produce CysLTs, the ability of fibrocytes, which do maintain some leukocyte markers, to make LTs is unknown. Fibrocytes were cultured overnight in SFM and supernatants were collected for analysis of total CysLTs and LTB 4 by specific EIA. Levels of CysLTs in overnight unstimulated cultures of fibrocytes were 57.2 Ϯ 10.8 pg/ml for CysLTs (Fig. 3) . However, when cells were treated with the Ca 2ϩ ionophore A23187 for 1 h, which provides a maximal stimulus for arachidonic acid release and LT biosynthesis, levels of CysLTs measured in the fibrocyte cultures were 470 Ϯ 63 pg/ml. For comparison, the levels of CysLTs produced by ionophore-treated fibroblast cultures were only 24.6 Ϯ 15 pg/ml. Levels of LTB 4 in the fibrocyte cultures were undetectable in the overnight unstimulated conditions and reached 25 Ϯ 6 pg/ml in the ionophore-stimulated conditions (data not shown). Thus, fibrocytes retain the ability to produce LTs and thus may be responsive to CysLT signaling in either an autocrine or paracrine manner.
LTs enhance fibrocyte proliferation
We examined the effect of endogenous LTs on fibrocyte proliferation by comparing basal proliferative rates of fibrocytes from WT (C57BL/6) and 5-LO Ϫ/Ϫ mice over 48 h in complete medium. Fibrocytes from 5-LO Ϫ/Ϫ mice exhibited a diminished proliferative capacity (Fig. 4A) . Thus, endogenous LT production can influence fibrocyte proliferation in vitro.
We next tested the influence of exogenous LTC 4 and LTD 4 on the proliferation of fibrocytes from WT (129SvEv, Fig. 4B ) and 5-LO Ϫ/Ϫ mice (Fig. 4C ). Exogenous addition of LTD 4 increased fibrocyte proliferation of both WT and 5-LO Ϫ/Ϫ fibrocytes in a dose-dependent manner within 24 h. In contrast, the addition of LTC 4 had little effect in either cell type. LTD 4 is the most potent agonist of the CysLT1 receptor (29) . The efficacy of LTD 4 compared with LTC 4 suggested that that these effects were being mediated via CysLT1 rather than CysLT2.
To verify receptor utilization, exogenous LTD 4 was added to fibrocytes from WT (C57BL/6) mice in the presence or absence of CysLT1-specific receptor antagonists MK571 (Fig. 5A) and Ly171883 (Fig. 5B ). Fibrocytes treated with 10 nM LTD 4 proliferated significantly more than fibrocytes did in SFM. Treatment with the CysLT1 antagonists MK571 or Ly171883 abrogated this LTD 4 enhancement of fibrocyte proliferation. The significant effects of the CysLT1 receptor antagonists to block all effects of exogenous LTD 4 confirm that LTD 4 signals proliferation of fibroblasts via the CysLT1 receptor.
Endogenous CysLTs do not influence fibrocyte proliferation in response to basic fibroblast growth factor (bFGF)
To determine whether fibrocytes from WT (129SvEv) and 5-LO Ϫ/Ϫ mice would show differences in proliferation to a different stimulus, fibrocytes were isolated from lung digests of both genotypes and tested for proliferation in response to either SFM or 100 ng/ml bFGF over 48 h. This stimulus increased fibrocyte proliferation in WT cells from 563 Ϯ 82 to 890 Ϯ 168 cpm (n ϭ 6). In cells from 5-LO Ϫ/Ϫ mice, bFGF stimulated proliferation from 450 Ϯ 54 to 993 Ϯ 321 cpm (n ϭ 6, p Ͻ 0.05 for bFGF compared with SFM in each group, but p ϭ NS between WT and 5-LO Ϫ/Ϫ cells plus bFGF). Thus, there was no significant difference in the response of fibrocytes from WT or 5-LO Ϫ/Ϫ mice in response to a different proliferative stimulus.
CysLTs do not enhance the differentiation of fibrocytes to fibroblasts in vitro
To determine whether CysLTs affect the rate of fibrocyte differentiation to fibroblasts, purified fibrocytes (Ͼ98% CD45 ϩ on day 0) from WT (C57BL/6 mice) were cultured in the presence or absence of 10 nM LTD 4 for 4 days. The percentage of CD45 ϩ cells remaining in each culture was then determined by flow cytometry. The percentages of CD45 ϩ cells remaining in the culture were similar for both treatments at day 4 (47.2% untreated vs 43.8% plus LTD 4 ), indicating that LTD 4 did not enhance the differentiation of CD45 ϩ fibrocytes to CD45 Ϫ fibroblasts.
LTs mediate fibrocyte chemotaxis in vitro
After identifying a role for LTs in fibrocyte proliferation, we next ascertained whether LTs affect the migration of fibrocytes. Using Boyden chamber assays, we demonstrated that LTD 4 stimulates migration of fibrocytes from WT (C57BL/6) mice (Fig. 6 ). The ability of LTD 4 to stimulate chemotaxis of fibrocytes was similar Fibrocytes were purified from lung mince cultures of WT (C57BL/6) mice and cultured at 2 ϫ 10 5 /ml in SFM in the presence or absence of 10 nM LTD 4 and either MK571 at 10 nM (A) or Ly171883 at 1 M (B) for 48 h, n ϭ 6. LTD 4 was able to significantly stimulate fibrocyte proliferation in both experiments. MK571 and Ly171883 both significantly reduced LTD 4 -stimulated proliferation (p Ͻ 0.05 for both by ANOVA).
to the potency of fibronectin which was used as a positive control for mesenchymal cell chemotaxis.
Fewer fibrocytes are cultured from the lungs of FITC-treated 5-LO Ϫ/Ϫ mice
We next analyzed the impact of LTs on fibrocyte accumulation by comparing fibrocyte numbers that could be cultured from the lungs in WT (129SvEv) and 5-LO Ϫ/Ϫ mice. We challenged both groups of mice with FITC and 5 days later performed a BAL. Cell pellets from the BAL were cultured for 14 days to allow leukocyte populations to die off and mesenchymal populations (fibrocytes) to expand. We found that the number of fibrocytes that can be cultured from 5-LO Ϫ/Ϫ mice is less than the number of fibrocytes that can be cultured from WT mice after FITC treatment (Fig. 7) . These results were verified in WT and 5-LO Ϫ/Ϫ mice on the C57BL/6 background. In brief, 17 Ϯ 0.5 ϫ 10 4 fibrocytes were cultured from FITC-treated C57BL/6 mice, whereas only 8.6 Ϯ 0.3 ϫ 10 4 fibrocytes were cultured from 5-LO Ϫ/Ϫ mice after FITC treatment ( p ϭ 0.0006). Because our previous results suggested that endogenous LTs could augment fibrocyte chemotaxis as well as proliferation in vitro, it was not clear whether these findings reflected a difference in the initial recruitment of fibrocytes to the lung or differences in the proliferative capacity of the fibrocytes during the 2-wk culture period.
LTs are not essential for fibrocyte recruitment in vivo
To analyze the initial recruitment of fibrocytes to the lung in response to FITC, we used flow cytometry to identify CD45 ϩ collagen 1 ϩ cells in either the BAL fluid after FITC treatment or in lung digests after FITC treatment. We compared the recruitment of fibrocytes in WT (C57BL/6) vs 5-LO Ϫ/Ϫ mice ( Fig.  8) and also the recruitment of fibrocytes in WT mice treated with FITC in the presence or absence of the CysLT1 receptor antagonist, MK571 (data not shown). We have previously demonstrated that day 5 represents the peak time point for fibrocyte accumulation after FITC treatment (6) . In the present study, we found that the number of fibrocytes recruited to the lung on day 5 after FITC treatment was not affected either by 5-LO genetic ablation or by MK571 treatment. Taken together, these results suggest that endogenous LTs influence proliferation rather than recruitment of fibrocytes.
Human fibrocytes proliferate in response to LTD 4
Our previous results indicated that human fibrocytes express both CysLT1 and CysLT2 (Fig. 2C) . In an effort to determine whether circulating human fibrocytes proliferate in response to LTD 4 , peripheral blood was collected from five normal volunteers and fibrocytes were isolated. Fibrocytes were then plated in quadruplicate at 20,000 cells/well in SFM or SFM containing 10 nM LTD 4 . FIGURE 6. LTD 4 stimulates fibrocyte chemotaxis in vitro. Fibrocytes were purified from lung mince cultures of WT (C57BL/6) mice. In brief, 1 ϫ 10 6 serum-starved fibrocytes were plated in the top well of Boyden chambers and chemotaxis through 8-m gelatin-coated filters was measured in response to fibronectin (100 mg/ml) or 10 nM LTD 4 . Ten highpowered fields were counted for each condition. LTD 4 stimulation of chemotaxis of fibrocytes is equivalent to that of fibronectin and statistically increased over control (SFM alone), p Ͻ 0.05. LTD 4 significantly stimulated the proliferation of the fibrocytes from each subject ( p ϭ 0.01 compared with SFM only for each). The means of the unstimulated and LTD 4 -stimulated proliferation rates for each subject are shown in Fig. 9 . Thus, both murine and human fibrocytes proliferate in response to LTD 4 .
Discussion
Fibrocytes have been shown convincingly to be recruited to murine lungs in response to fibrotic injury (6, 7) . Adoptive transfer of fibrocytes can augment the development of fibrosis in animal models (30) . In addition, recently published data demonstrate that circulating fibrocytes are elevated in patients with IPF compared with normal volunteers (31) . Thus, both murine and human studies suggest a critical role for fibrocytes in the development of fibrotic lung disease. As such, a better understanding of the factors which recruit and activate these cells is needed. Fibrocytes may be able to augment fibrosis through a variety of mechanisms. First, they contribute to collagen production directly. Second, they secrete profibrotic and proinflammatory factors which likely augment fibrotic responses. Third, they may differentiate into myofibroblasts to participate in lung contraction and extracellular matrix deposition. Increases in the total number of fibrocytes within the lung, either by direct chemotactic mechanisms or in situ proliferation, would likely augment fibrotic responses. Our studies are the first to demonstrate the ability of fibrocytes to make and respond to LTs.
The goal of this research was to test the hypothesis that LTs regulate fibrocytes in a manner that is critical to the development of pulmonary fibrosis. We began our studies by demonstrating that LT production was specifically stimulated by the instillation of FITC as it is by bleomycin (17) and that LTs play a causal role in FITC-induced fibrosis. Using this model, we showed that fibrocytes produce CysLTs and respond to them in an autocrine or a paracrine fashion by proliferating and migrating in vitro. We also demonstrate that bFGF is a fibrocyte mitogen. These are the first studies to provide evidence for any factor that regulates murine fibrocyte proliferation. One previous report demonstrates that addition of endothelin 1 or TGF␤1 to human circulating fibrocytes can stimulate BrdU incorporation over a period of 4 days (8). It is interesting to note that in other systems, endothelin 1 and TGF␤1 have been noted to up-regulate CysLT production (32, 33) . Thus, it is possible that CysLTs are common effector molecules for fibrocyte proliferation, but they do not enhance fibrocyte differentiation into fibroblasts in vitro. Our in vivo studies show that the initial recruitment of fibrocytes is not inhibited in the absence of LTs. Because fibrocytes can be recruited to sites of FITC-induced injury by CCR2, CXCR4, and CCR7-mediated signals (6, 7), we speculate that factors such as CCL12 or stromal cell-derived factor 1 may be responsible for fibrocyte recruitment in the absence of LTs. As a result, the fact that fewer fibrocytes can be cultured from BAL of 5-LO Ϫ/Ϫ mice after FITC-induced injury likely reflects reduced proliferation rates. Given these findings, we propose that protection from fibrosis exhibited by 5-LO Ϫ/Ϫ mice (Ref. 17 and this study) or mice treated with CysLT1 antagonists (18, 19) likely results, at least in part, from diminished in situ proliferation of fibrocytes in the challenged lungs.
Fibrocytes are cells that express both mesenchymal and leukocyte markers. Our studies demonstrate that fibrocytes, like leukocytes, retain the ability to produce LTs. This is the first description of eicosanoid production by this novel cell type. The ability of fibrocytes to produce LTs would be expected to augment the chemotaxis of both leukocytes and resident fibroblasts. Our studies confirm that resident lung fibroblasts express both CysLT1 and CysLT2 receptors. In addition, previous reports have demonstrated that CysLTs can augment proliferation of resident lung fibroblasts (10 -12) . The secretion of LTB 4 may serve as a potent neutrophil chemotactic molecule (34) . The role that neutrophils play in fibrotic responses is unclear, but certainly the release of reactive oxygen species and neutrophil elastase may contribute to local tissue injury (35) . The fact that CysLTs are elevated in fibrotic lungs is well documented in both murine and human studies (12, 17) and in the mouse, CysLTs are the predominant LT generated in the lung (17) . Thus, it is likely that the recruitment of fibrocytes to the lung via any chemotactic stimulus would result in the local expansion of these cells via CysLT-mediated proliferation. Since fibrocytes have also been shown to be recruited to airways in the setting of asthma (8) , the presence of CysLTs in this disease would also be expected to enhance the local proliferation of fibrocytes and this may be an important aspect of the airway remodeling that occurs in this disease setting. In this regard, it is important to note that human fibrocytes also proliferate in response to LTD 4 .
Our results demonstrate that LTD 4 is a more potent mitogen for fibrocytes than LTC 4 . Additionally, CysLT1 receptor antagonists block the effects of LTD 4 on fibrocyte proliferation. These results suggest that LTD 4 mediates its effects on fibrocytes solely via the CysLT1 receptor. We speculate that the proliferative effects of LTD 4 on fibrocytes are important to the pathogenesis of lung fibrosis. We used two different CysLT1 receptor antagonists in these studies, MK571 and Ly171883. MK571 has previously been shown to be a competitive inhibitor of the multi-drug resistanceassociated protein ATP-binding cassette transporter, which can regulate CysLT secretion, but only at doses above 1 M (36). Similarly, Ly171883 has been shown to be both a PPAR-␣ (37) and peroxisome proliferator-activated receptor ␥ (38) ligand, but again at doses 10 -10,000-fold higher than used in our studies. Thus, we believe the findings that both of these inhibitors blocked LTD 4 -induced proliferation when used at current doses strongly support a role for CysLT1-mediated proliferative effects.
5-LO Ϫ/Ϫ mice are protected from lung fibrosis induced by both bleomycin (17) and FITC at day 21 postchallenge. Our studies provide mechanistic insight into these observations and suggest that 5-LO Ϫ/Ϫ mice are protected because LTD 4 -induced mitogenic effects on fibrocytes mediated via CysLT1 are lacking in the 5-LO Ϫ/Ϫ mice. Our results are consistent with previous studies which demonstrated that dosing of mice with either of the CysLT1 receptor antagonists MK571 (18) or montelukast (19) limited bleomycin-induced lung injury and fibrosis in mice. Additionally, our findings are consistent with the observation that cPLA2 Ϫ/Ϫ mice have reduced levels of LTs in their lungs in response to bleomycin challenge and are protected from fibrosis (39) . LTC 4 synthasedeficient mice are similarly protected from bleomycin-induced fibrosis (40) . However, our findings are not consistent with those of Beller et al. (40) , who demonstrated that CysLT1 Ϫ/Ϫ mice showed evidence of septal thickening and deposition of reticular fibers that was enhanced compared with WT mice at day 12 after bleomycin treatment. Nor are our observations consistent with the findings from this same group (41) that CysLT2 Ϫ/Ϫ mice were protected from bleomycin-induced fibrosis on day 12. Based on our findings of CysLT2 on resident fibroblasts, we would anticipate that CysLT2 Ϫ/Ϫ mice might show some protection from fibrosis. However, it is not clear why the reported results in the CysLT1 Ϫ/Ϫ mice are different from the results using CysLT1 antagonists in vivo (18, 19) or our results in the 5-LO Ϫ/Ϫ mice, but this may reflect differences in the time points of assessment (day 12 vs day 21), model systems used, or methodology (Ashcroft scores vs hydroxyproline assays).
There remains a critical need to identify new modes of therapy for fibrotic lung disorders. Our present findings provide a new rationale for using LT inhibitors or CysLT1 receptor antagonists in antifibrotic therapy. One potential advantage of targeting longterm therapy to blockade of the CysLT1 pathway rather than blockade of all LT production may be the ability to deliver antifibrotic therapy without diminishing the ability of LTB 4 to participate in innate immune actions on AMs and polymorphonuclear neutrophils.
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